Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Penicillamine SCHEMBL4344 | 1.00 | — | — | |
| Penicillamine SCHEMBL4343 | 1.00 | — | — | |
| Dl-Penicillamine SCHEMBL159653 | 1.00 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Dl-Penicillamine SCHEMBL57527 | 1.00 | — | — | |
| Penicillamine SCHEMBL129296 | 1.00 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL603349 | 1.00 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL10789333 | 0.97 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL3138111 | 0.97 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL6654084 | 0.97 | — | — | |
| Penicillamine SCHEMBL7932147 | 0.97 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| EP-3921331-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020160685-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2020-08-13 | — | — | WO | disclosed |
| CN-101360487-A | Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms | CHILDRENS MEDICAL CT (US) | 2009-02-04 | — | — | CN | disclosed |
| CN-101291683-A | Methods and compositions for treating disease | NEOPRO LABS LLC (US) | 2008-10-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | ALDH1A1 1872/4885PTGS1 105/4885MAPT 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.